Ciriano Cerdà Estel la, Zajc Alenka Lavra, Finotello Riccardo, Macdonald Kirsty, Lyseight Filipa, Van Den Steen Nele, Sanchez Gonzalez Katia, Marrington Mary, Grant Jessica
Northwest Veterinary Specialists, Part of Linnaeus Veterinary Limited, Ashville Point, Beechwood, Sutton Weaver, Runcorn WA7 3FW, UK.
Department of Small Animal Clinical Sciences, Department of Veterinary Anatomy Physiology and Pathology, Institute of Infection Veterinary and Ecological Sciences, University of Liverpool, Chester High Rd, Neston CH64 7TE, UK.
Vet Sci. 2023 Aug 21;10(8):529. doi: 10.3390/vetsci10080529.
Cyclooxygenase (COX) inhibitors have been demonstrated to have antitumour activity in canine urothelial cell carcinoma (UCC), given as a sole treatment or in combination with chemotherapy. The purpose of this retrospective multi-institutional study was to assess the efficacy of meloxicam in combination with mitoxantrone or vinblastine as a first-line treatment for non-resectable canine UCC. Gastrointestinal adverse effects (AEs) of these treatment combinations were also assessed. A total of 28 dogs met the inclusion criteria, 21/28 dogs received mitoxantrone and meloxicam, and 7/28 received vinblastine and meloxicam. Tumour response (TR) and AE were evaluated according to Veterinary Co-Operative Oncology Group (VCOG) criteria. The endpoint of the study was the time to tumour progression (TTP). The mitoxantrone-group induced 24% partial response and 62% stable disease, while the vinblastine-group induced 14% and 86%, respectively. Median TTP was 84 days (mitoxantrone and meloxicam, 70 days; and vinblastine and meloxicam, 178 days). The presence of metastatic disease significantly decreased TTP ( = 0.007). Gastrointestinal AEs were reported in 21.4% of the patients, with the most common being VCOG grade 1-2 diarrhoea. Meloxicam is a well-tolerated NSAID when combined with mitoxantrone or vinblastine as first-line treatment for non-resectable canine UCC.
环氧化酶（COX）抑制剂已被证明在犬尿路上皮细胞癌（UCC）中具有抗肿瘤活性，可单独使用或与化疗联合使用。这项回顾性多机构研究的目的是评估美洛昔康联合米托蒽醌或长春碱作为不可切除犬UCC一线治疗的疗效。还评估了这些治疗组合的胃肠道不良反应（AE）。共有28只狗符合纳入标准，21/28只狗接受了米托蒽醌和美洛昔康治疗，7/28只狗接受了长春碱和美洛昔康治疗。根据兽医合作肿瘤学组（VCOG）标准评估肿瘤反应（TR）和AE。研究的终点是肿瘤进展时间（TTP）。米托蒽醌组诱导24%的部分缓解和62%的病情稳定，而长春碱组分别诱导14%和86%。中位TTP为84天（米托蒽醌和美洛昔康，70天；长春碱和美洛昔康，178天）。转移性疾病的存在显著缩短了TTP（=0.007）。21.4%的患者报告了胃肠道AE，最常见的是VCOG 1-2级腹泻。美洛昔康与米托蒽醌或长春碱联合作为不可切除犬UCC的一线治疗时，是一种耐受性良好的非甾体抗炎药。
